Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.72B 2.4B 2.23B 2.05B 3.84B 264B 3.91B 26.62B 10.38B 129B 10.23B 10.01B 446B P/E 2026 *
106x
P/E 2027 * 31.5x
Enterprise Value 2.72B 2.4B 2.23B 2.05B 3.84B 264B 3.91B 26.62B 10.38B 129B 10.23B 10.01B 446B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.66x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+0.53%
1 week-2.12%
Current month+1.46%
1 month+6.09%
3 months-6.35%
6 months-2.20%
Current year-5.05%
1 week 46.07
Extreme 46.07
48.79
1 month 44.49
Extreme 44.49
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.53
Extreme 32.53
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

321,750 0.5738%
13/03/26 Others

Founder

60,000 0.1070%
12/03/26 Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%-2.12%+43.13%+54.17% 2.72B
+2.36%+2.23%+55.37%+18.20% 315B
+1.72%-0.61%+27.81%-10.31% 67.93B
+3.88%+4.26%+38.05%+88.48% 9.23B
+0.15%-1.81%+2.97%-4.85% 8.43B
+3.78%+1.92%-21.25%-6.67% 4.07B
+0.07%-9.52%-5.52%+22.21% 3.77B
+1.71%+2.73%-42.88%+11.90% 3.54B
-0.30%-6.60%+4.82%-10.21% 2.13B
+0.61%-5.82%-17.93%+37.29% 1.95B
Average +1.09%+1.90%+8.46%+20.02% 41.86B
Weighted average by Cap. -0.52%+2.63%+46.66%+14.58%

Financials

2026 *2027 *
Net sales 867M 763M 709M 652M 1.22B 83.98B 1.24B 8.47B 3.3B 40.96B 3.26B 3.19B 142B 1.02B 900M 836M 769M 1.44B 99.06B 1.47B 9.99B 3.9B 48.32B 3.84B 3.76B 168B
Net income 25.92M 22.8M 21.18M 19.48M 36.53M 2.51B 37.19M 253M 98.79M 1.22B 97.32M 95.22M 4.25B 92.99M 81.79M 75.98M 69.88M 131M 9.01B 133M 909M 354M 4.39B 349M 342M 15.24B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
23/07/26 US$47.19 +0.53% 463,336
22/07/26 US$46.94 -1.94% 430,060
21/07/26 US$47.87 +0.95% 450,290
20/07/26 US$47.42 -1.29% 618,820
17/07/26 US$48.04 -0.35% 439,397
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
47.19USD
Average target price
63.50USD
Spread / Average Target
+34.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock